Business Context and Reporting Period
This Form 8-K was filed by Genesis Biopharma, Inc. (not IOVANCE Biotherapeutics, Inc.) on September 17, 2010. The report details the closing of a private placement offering entered into on the same date.
Key Financial Metrics
The filing discloses the following capital raise metrics:
- Total Proceeds: $700,000.50
- Common Stock Issued: 933,341 shares
- Series A Warrants: 466,674 warrants exercisable at $1.00 per share
- Series B Warrants: 466,674 warrants exercisable at $1.25 per share
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in equity capital and potential future share count due to the issuance of common stock and warrants to accredited investors. The company granted "piggy-back" registration rights to investors for the shares and underlying warrant stock.
Outlook, Risks, and Unusual Items
The securities were issued in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933, Regulation S, and Rule 506 of Regulation D. The offering did not involve general solicitation. No specific forward-looking guidance or management commentary regarding future operations is included in this specific filing.
Investor Verification Checklist
- Verify the current share count and dilution impact of the 933,341 new shares plus 933,348 potential warrant shares.
- Confirm the company's current cash position post-transaction to assess runway.
- Review the attached Subscription Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Check subsequent filings for the exercise status of the Series A and Series B warrants.